Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMACOR vs BEKYREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omega-3-acid ethyl esters (EPA and DHA) reduce hepatic triglyceride synthesis by inhibiting acyl-Co A:1,2-diacylglycerol acyltransferase and increasing beta-oxidation. They also decrease very-low-density lipoprotein (VLDL) secretion and enhance triglyceride clearance from circulating VLDL particles.
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
FDA: Adjunct to diet for reduction of triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/d L).,Off-label: Secondary prevention of cardiovascular events in patients with hypertriglyceridemia or high cardiovascular risk.
Treatment of chronic kidney disease in patients with type 2 diabetes,Reduction of albuminuria in chronic kidney disease
4 g orally once daily or 2 g orally twice daily, taken with meals. Each capsule contains 1 g of omega-3-acid ethyl esters (approximately 465 mg eicosapentaenoic acid and 375 mg docosahexaenoic acid).
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
Terminal elimination half-life: ~55–75 hours for EPA and DHA (beta-phase). Clinical context: steady-state achieved after 4–8 weeks; half-life supports once-daily dosing.
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in Cr Cl <30 m L/min)
Omega-3-acid ethyl esters are primarily hydrolyzed by pancreatic lipase to free fatty acids (EPA and DHA), which are then absorbed and incorporated into chylomicrons. They undergo hepatic metabolism via beta-oxidation. CYP450 involvement is minimal.
Primarily metabolized by CYP3A4; minor contributions from CYP2C8 and CYP2C9.
Primarily fecal as unchanged drug and metabolites; <5% renal. Biliary excretion accounts for ~90% of elimination via feces, with minimal urinary excretion (0.5–2%).
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
Highly protein-bound (>99%) primarily to albumin.
95% bound to albumin and alpha-1-acid glycoprotein
Vd: ~0.2–0.3 L/kg (EPA), ~2–3 L/kg (DHA). Clinical meaning: extensive tissue distribution, especially in adipose and cardiac tissues.
0.8-1.2 L/kg (indicates extensive tissue distribution)
Oral: 50–100% (enhanced with fatty meal; absolute bioavailability not determined).
Oral: 60% (range 50-70%; first-pass metabolism reduces bioavailability)
No dose adjustment required for any degree of renal impairment. Use caution in patients with renal disease due to potential for increased bleeding risk.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
Contraindicated in patients with Child-Pugh class C (severe) hepatic impairment. For Child-Pugh A or B, no dose adjustment is recommended, but monitor liver function tests periodically.
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg/kg intravenously every 4 weeks; Child-Pugh C: not recommended.
Safety and efficacy not established in pediatric patients. Not recommended for use in children.
Safety and efficacy not established in pediatric patients under 18 years.
No specific dose adjustment recommended. Monitor for potential drug interactions, especially with anticoagulants, due to increased bleeding risk. Start at lower end of dosing range if elderly patient has significant comorbidity or polypharmacy.
No specific dose adjustment required; consider age-related renal function and comorbidities.
No FDA black box warning.
None.
Increased bleeding risk (monitor patients on anticoagulants).,Atrial fibrillation in patients with prior history or at high risk.,Persistent elevations of ALT or AST, especially with other hepatotoxic drugs.,Hypersensitivity reactions including anaphylaxis.,Fish allergy (capsules contain fish oil).
Hyperkalemia: Monitor serum potassium regularly; avoid use with strong CYP3A4 inhibitors or potassium supplements.,Acute kidney injury: May occur; assess renal function before initiation.,Adrenal insufficiency: Not studied in patients with adrenal disorders.,Pregnancy: Limited data; avoid use unless benefit outweighs risk.
Hypersensitivity to omega-3-acid ethyl esters or any component.,Acute pancreatitis with marked hypertriglyceridemia (consider if triglycerides >500 mg/d L and chylomicronemia).
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin),Serum potassium >5.0 m Eq/L at initiation,e GFR <15 m L/min/1.73 m² (not studied),Hypersensitivity to balcinrenone or any excipient
Avoid high-fat meals as they may increase triglyceride levels. No specific food interactions known, but consistency in timing with meals is recommended.
No known food interactions. Avoid grapefruit juice if patient is on concurrent CYP3A4 substrates (though bevacizumab is not metabolized by CYP enzymes). Maintain adequate hydration to reduce risk of constipation, a common side effect.
FDA Pregnancy Category C. No evidence of teratogenicity in animal studies at doses up to 10 times the human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. Omega-3-acid ethyl esters may inhibit prostaglandin synthesis and delay labor. Third trimester use may increase risk of bleeding in mother and neonate.
First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for fetal growth restriction and oligohydramnios.
Not recommended during breastfeeding. Omega-3 fatty acids are excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infant. Consider alternative treatment or discontinue nursing.
No human data on excretion in breast milk. M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in nursing infant.
No specific dose adjustments recommended for pregnancy-induced pharmacokinetic changes. Use with caution as pregnancy may alter lipid profiles; monitor triglyceride levels and adjust dose accordingly.
No specific dose adjustments recommended based on pharmacokinetic changes. However, monitor therapeutic effect and adjust dose as needed based on clinical response and tolerability.
Omacor (omega-3-acid ethyl esters) is indicated as an adjunct to diet for severe hypertriglyceridemia (≥500 mg/d L). Monitor LDL-C levels as they may increase during therapy; adjust statin dose if needed. Administer with meals to enhance absorption and reduce gastrointestinal side effects. Avoid use in patients with fish or shellfish allergy. May prolong bleeding time; monitor in patients on anticoagulants.
BEKYREE (bevacizumab-awwb) is a biosimilar to bevacizumab. Monitor for hypertension, proteinuria, and bleeding. Discontinue 28 days prior to elective surgery. Avoid use in patients with recent hemoptysis or serious hemorrhage. Infusion reactions may occur; premedicate with antihistamines and acetaminophen as per protocol.
Take with food to improve absorption and reduce burping or fishy taste.,Do not take if you have an allergy to fish or shellfish.,Report unusual bleeding or bruising, especially if you are on blood thinners.,Do not substitute with over-the-counter fish oil supplements as they are not equivalent.,Continue dietary modifications and exercise as part of your treatment plan.
Tell your doctor if you have a history of bleeding problems, blood clots, or recent surgery.,Avoid taking aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, coughing up blood, or black/tarry stools immediately.,Women of childbearing age must use effective contraception during therapy and for 6 months after last dose.,Do not breastfeed during treatment and for 6 months after the last dose.,Monitor for signs of hypertension (severe headache, blurred vision) and proteinuria (foamy urine).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMACOR vs BEKYREE, answered by our medical review team.
OMACOR is a Antilipemic that works by Omega-3-acid ethyl esters (EPA and DHA) reduce hepatic triglyceride synthesis by inhibiting acyl-Co A:1,2-diacylglycerol acyltransferase and increasing beta-oxidation. They also decrease very-low-density lipoprotein (VLDL) secretion and enhance triglyceride clearance from circulating VLDL particles.. BEKYREE is a Antilipemic Agent that works by BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMACOR and BEKYREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMACOR is: 4 g orally once daily or 2 g orally twice daily, taken with meals. Each capsule contains 1 g of omega-3-acid ethyl esters (approximately 465 mg eicosapentaenoic acid and 375 mg docosahexaenoic acid).. The standard adult dose of BEKYREE is: 1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OMACOR and BEKYREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OMACOR is classified as Category C. FDA Pregnancy Category C. No evidence of teratogenicity in animal studies at doses up to 10 times the human dose. There are no adequate and well-controlled studies in pregnant wome. BEKYREE is classified as Category C. First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.